Regulation of TERT Expression by MEK1/2 and c-Myc:MAX in Human Pluripotent Stem Cells

Study Background and Research Question

Telomerase, a ribonucleoprotein enzyme, maintains telomere length and thereby supports the long-term proliferative capacity of human embryonic stem cells (hESCs). The catalytic subunit of telomerase is encoded by the TERT gene, whose transcription is tightly regulated during development. While mature telomerase is essential for stem cell function and tissue renewal, aberrations in its regulation have been implicated in telomere biology disorders and age-associated diseases. Despite its importance, the mechanisms governing TERT expression in normal human stem cells remain incompletely understood. Prior evidence indicates that MAPK pathway activity, particularly through MEK/ERK signaling, influences TERT expression in induced pluripotent stem cells, but the precise regulatory network in hESCs had yet to be defined. The study by Kotian et al. (2024) addresses this knowledge gap by elucidating how MEK1/2 kinases and the c-Myc:MAX transcriptional complex prevent polycomb-mediated repression of TERT in hESCs.

Key Innovation from the Reference Study

The pivotal innovation in this research lies in demonstrating that MEK1/2 kinase activity, in concert with c-Myc:MAX, actively restrains the polycomb repressive complex 2 (PRC2) and its enzymatic subunit EZH2 from depositing the histone H3K27me3 mark at the TERT promoter in human pluripotent stem cells. This combinatorial control ensures robust TERT transcription, sustaining telomerase activity required for stem cell self-renewal. Notably, the study connects canonical MAPK signaling and c-Myc-driven transcription to direct modulation of chromatin state at a key developmental gene locus, establishing a mechanistic bridge between signal transduction, transcription factor activity, and epigenetic repression.

Methods and Experimental Design Insights

The authors employed a multifaceted approach to dissect TERT regulation in hESCs. Pharmacological inhibition of MEK1/2 and ERK1/2 kinases was used to probe the role of MAPK signaling. Quantitative PCR (qPCR) measured TERT mRNA levels following kinase inhibition. Chromatin immunoprecipitation (ChIP) assays quantified the enrichment of histone modifications—specifically, H3K27 trimethylation (H3K27me3) and acetylation (H3K27ac)—at the TERT promoter. To evaluate the involvement of polycomb repression, the team utilized PRC2 inhibitors and monitored their impact on TERT expression and chromatin state. Furthermore, a selective c-Myc:MAX dimerization inhibitor was applied to determine the requirement for this transcription factor complex in TERT regulation. Recruitment of MAX to the TERT locus was assessed by ChIP, providing evidence for direct cis-regulatory interactions.

Core Findings and Why They Matter

The study provides several interlocking findings (Kotian et al., 2024):

• MEK/ERK Inhibition Represses TERT Transcription: Treatment with MEK1/2 or ERK1/2 inhibitors led to significant reductions in TERT mRNA, establishing a requirement for MAPK signaling in maintaining telomerase gene expression in hESCs.
• Epigenetic Silencing via H3K27me3: MEK inhibition triggered a marked increase in H3K27me3 at the TERT proximal promoter, a modification deposited by the PRC2 complex (with EZH2 as the methyltransferase catalytic subunit). This was accompanied by a decrease in the activating mark H3K27ac, suggesting a shift toward a repressive chromatin state.
• PRC2 Inhibition Partially Restores TERT: Pharmacological inhibition of PRC2 partially rescued TERT expression in the context of MEK inhibition, directly implicating polycomb-mediated repression in the loss of telomerase gene activity.
• c-Myc:MAX Complex Prevents Repression: Inhibition of c-Myc:MAX dimerization led to rapid H3K27me3 deposition at TERT and decreased TERT transcription. ChIP data showed reduced MAX binding at TERT, supporting a model where the c-Myc:MAX complex acts locally to maintain an open chromatin state and prevent PRC2 targeting.

These findings demonstrate that TERT regulation in hESCs is not solely a function of transcription factor binding, but is tightly linked to chromatin state, modulated by crosstalk between MAPK signaling, c-Myc:MAX, and polycomb repression. This insight is especially relevant for epigenetic cancer research and for understanding how dysregulation of these pathways may contribute to oncogenesis or stem cell exhaustion.

Comparison with Existing Internal Articles

Recent internal literature—such as "GSK343 and the Interplay of EZH2 Inhibition with TERT Regulation"—has explored the utility of selective EZH2 inhibitors like GSK343 in dissecting the PRC2 pathway and histone H3K27 trimethylation inhibition within the context of cancer epigenetics. These resources highlight how pharmacological targeting of EZH2 can modulate TERT expression, mirroring the findings that PRC2 activity is a key determinant of telomerase gene repression. Additional reviews, for instance "GSK343 and the Epigenetic Switch: Precision EZH2 Inhibition", provide mechanistic context for how GSK343 facilitates the study of chromatin-based gene regulation, particularly in models of cancer cell proliferation inhibition and telomerase control. The present study extends this knowledge by pinpointing the upstream signaling and transcriptional events that gate PRC2 access to the TERT promoter in stem cells, offering a more comprehensive view of regulatory hierarchy.

Limitations and Transferability

While the study establishes a robust mechanistic framework in human pluripotent stem cells, several limitations should be noted. The experiments were conducted in hESC models, and while the results are likely generalizable to other pluripotent and progenitor cells, further work is required to confirm these regulatory relationships in adult stem cells and differentiated lineages. The pharmacological tools used, while selective, may have off-target effects, necessitating validation with genetic models. Moreover, the partial rescue of TERT by PRC2 inhibition suggests that additional factors contribute to TERT silencing upon MEK/ERK blockade. The direct applicability of these findings to cancer models, where TERT reactivation is a hallmark, remains an important but untested avenue. Thus, while the mechanistic connections between MAPK, c-Myc:MAX, and PRC2/EZH2 are clear in hESCs, context-specific nuances should be considered when translating these findings to other biological systems.

Protocol Parameters

• MEK1/2 inhibition: Apply selective small-molecule MEKi at concentrations validated for robust pathway suppression in hESCs; monitor for TERT mRNA reduction within 24–48 hours.
• ChIP assays: Use validated antibodies for H3K27me3 and H3K27ac; quantify enrichment at the TERT proximal promoter following pharmacological treatments.
• PRC2 inhibition: Employ selective EZH2/PRC2 inhibitors (e.g., GSK343) at concentrations that reduce H3K27me3 without compromising cell viability; assess TERT expression rescue as a readout.
• c-Myc:MAX inhibition: Treat with dimerization inhibitors at sub-cytotoxic doses; evaluate both chromatin state changes and TERT mRNA levels.
• Gene expression analysis: Use qPCR with validated TERT primer sets; normalize to housekeeping genes for accurate quantification.

Research Support Resources

For researchers aiming to model or manipulate polycomb-mediated repression of TERT, selective EZH2 inhibitors offer valuable tools. GSK343 (SKU A3449) is a potent, cell-permeable, and SAM-competitive EZH2 inhibitor that has been widely used to investigate H3K27me3-dependent silencing in both stem cell and cancer biology contexts. As reported in the product documentation, GSK343 enables precise modulation of PRC2 activity, supporting workflows focused on histone methylation, telomerase regulation, and epigenetic cancer research. APExBIO supplies GSK343 as a solid, optimized for in vitro assays and mechanistic studies of EZH2 function in chromatin biology.